Nagpur: With a fresh surge in Covid cases, the first consignment of the Molnupiravir anti-virus drug, which recently received a nod from the regulator in India, was distributed among several main hospitals in the city, raising hopes on the virus and the new Omicron variant .
Oral drugs are indicated for patients who are not vaccinated but experts feel they can work with miracles even for vaccinated populations if used wisely.
This drug will be distributed from Nagpur to the rest of Vidarbha and Chhattisgarh.
Nitin Gandhi from the Medicine Institute of Gupta, one of the first distributors for Hetero Healthcare Limited Movfor, Molnupiravir’s commercial brand, to be supplied to a doctor and hospital, said there was a stable request that now grows.
It was studied, at least two pharmaceutical companies, Dr.
Reddy’s and Cipla were also expected to bring Molnupiravir in the city immediately.
Professor Dr.
Prashant Joshi, Head of the Department of Medicine, AIIMS, said Molnupiravir reportedly reduced hospitalization substantially.
“Molnupiravir has been shown to reduce the development of the disease,” said Dr.
Joshi added that AIIMS will also immediately have their own stock.
Dr.
Joshi also said Molnupiravir was found to be useful if given within five days after the onset of symptoms in adults who were not treated in hospitals and were not vaccinated with Covid-19 which were light to medium and had at least one risk factor for severe infections.
“This drug will reduce the risk of hospitalization or death in accordance with the phase III trial,” he added 800 mg drugs needed per day.
Dr.
Nitin Shinde’s specialist emphasizes new drugs can reduce hospitalization with at least 30% if given within five days of symptoms for five days.
“This new drug is known to stop the growth of the virus,” said Dr.
Shinde added patients with limited therapeutic scope that can be used on them will greatly benefit.
“Pregnant women and underage children cannot be given this medicine,” Dr Shinde said.
Senior Pulmonologologist Dr.
Ashok Arbat said the new drug is cost-effective and with side effects and relatively less risks.
Explain the way Molnupiravir works, Dr.
Nitin Wadaskar Internal Medicine Specialist said the drug acts revolved around the obstacles of replication of viruses and mutagenic actions for self-destruction.
“This drug is indicated for patients who are not treated in hospitals with Covid-19 and SPO2 below 93 have a higher risk of development,” he added that the breastfeeding mothers must avoid drugs.
“The dose is four 200mg capsules twice a day for five days,” he said.
This drug was discussed in one of the meetings attended by the Guardian Minister, in accordance with Covid Force Member, Dr.
Ravindra Sarnaik.
“We need to scientifically observe the effects of the drug and various other properties along with suitability before recommending it.
The state assignment unit and government guidelines also need to be referred,” he said.
Molnupiravir reaches the city, updating expectations against Covid
